Theravance Biopharma, Inc. (TBPH)
TBPH Stock Price Chart
Explore Theravance Biopharma, Inc. interactive price chart. Choose custom timeframes to analyze TBPH price movements and trends.
TBPH Company Profile
Discover essential business fundamentals and corporate details for Theravance Biopharma, Inc. (TBPH) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 May 2014
Employees
97.00
Website
https://www.theravance.comCEO
Rick E. Winningham
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
TBPH Financial Timeline
Browse a chronological timeline of Theravance Biopharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.03, while revenue estimate is $19.19M.
Earnings released on 12 Aug 2025
EPS came in at -$0.08 surpassing the estimated -$0.14 by +42.86%, while revenue for the quarter reached $26.20M , beating expectations by +39.87%.
Earnings released on 8 May 2025
EPS came in at -$0.17 falling short of the estimated -$0.11 by -54.55%, while revenue for the quarter reached $15.39M , missing expectations by -4.42%.
Earnings released on 26 Feb 2025
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $18.75M , beating expectations by +9.72%.
Earnings released on 12 Nov 2024
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%, while revenue for the quarter reached $16.87M , missing expectations by -38.25%.
Earnings released on 5 Aug 2024
EPS came in at -$0.13 falling short of the estimated -$0.09 by -44.44%, while revenue for the quarter reached $14.26M , missing expectations by -7.73%.
Earnings released on 13 May 2024
EPS came in at -$0.09 surpassing the estimated -$0.19 by +52.63%, while revenue for the quarter reached $14.50M , beating expectations by +3.89%.
Earnings released on 26 Feb 2024
EPS came in at $0.03 falling short of the estimated $0.04 by -14.36%, while revenue for the quarter reached $17.57M , missing expectations by -0.65%.
Earnings released on 7 Nov 2023
EPS came in at -$0.01 surpassing the estimated -$0.10 by +90.00%, while revenue for the quarter reached $15.69M , missing expectations by -11.24%.
Earnings released on 7 Aug 2023
EPS came in at -$0.13 surpassing the estimated -$0.16 by +18.75%, while revenue for the quarter reached $13.75M , missing expectations by -10.72%.
Earnings released on 8 May 2023
EPS came in at -$0.24 surpassing the estimated -$0.27 by +11.11%, while revenue for the quarter reached $10.42M , missing expectations by -24.73%.
Earnings released on 27 Feb 2023
EPS came in at -$0.21 falling short of the estimated -$0.20 by -5.00%, while revenue for the quarter reached $14.65M , missing expectations by -4.90%.
Earnings released on 7 Nov 2022
EPS came in at -$0.21 surpassing the estimated -$0.22 by +4.55%, while revenue for the quarter reached $12.45M , beating expectations by +5.43%.
Earnings released on 4 Aug 2022
EPS came in at -$0.04 surpassing the estimated -$0.06 by +33.33%, while revenue for the quarter reached $11.05M , missing expectations by -11.56%.
Earnings released on 5 May 2022
EPS came in at -$0.24 falling short of the estimated -$0.12 by -100.00%, while revenue for the quarter reached $13.20M , missing expectations by -8.34%.
Earnings released on 23 Feb 2022
EPS came in at -$0.43 falling short of the estimated -$0.30 by -43.33%, while revenue for the quarter reached $14.95M , beating expectations by +10.81%.
Earnings released on 3 Nov 2021
EPS came in at -$0.48 surpassing the estimated -$0.60 by +20.00%, while revenue for the quarter reached $13.19M , missing expectations by -18.05%.
Earnings released on 3 Aug 2021
EPS came in at -$0.80 surpassing the estimated -$0.96 by +16.67%, while revenue for the quarter reached $12.91M , meeting expectations.
Earnings released on 4 May 2021
EPS came in at -$1.24 falling short of the estimated -$1.05 by -18.10%, while revenue for the quarter reached $14.26M , beating expectations by +22.09%.
Earnings released on 23 Feb 2021
EPS came in at -$0.92 surpassing the estimated -$1.03 by +10.68%, while revenue for the quarter reached $18.73M , missing expectations by -8.93%.
Earnings released on 5 Nov 2020
EPS came in at -$1.16 falling short of the estimated -$0.98 by -18.37%, while revenue for the quarter reached $18.26M , beating expectations by +19.59%.
TBPH Stock Performance
Access detailed TBPH performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.